Genome-wide association study identifies genetic variants which predict the response of bone mineral density to teriparatide therapy
Authors' conclusion
Genetic factors influence the response to TPTD at the lumbar spine and hip with a magnitude of effect that is clinically relevant.
Study context
- Population
- Patients with osteoporosis treated with teriparatide (TPTD), three referral centres
- Participants
- 437 patients
- Outcome
- Response of BMD to TPTD at the lumbar spine and hip
Methodological detailstwo-stage, three referral centres
- Two-stage
- Three referral centres
Main finding
As reported in the abstract
Spine BMD response to TPTD: rs6430612 (chromosome 2, near CXCR4)
- Association at genome-wide significance, beta
- −0.35 (−0.47 to −0.23)
- P
- p=9.2×10-9
Further findings
Femoral neck and total hip bone mineral density (BMD) response: rs6430612
- Associated, P
- P = 0.007
Femoral neck BMD response: rs73056959 (chromosome 19 locus)
- Beta
- −1.61 (−2.14 to −1.07)
- P
- P = 3.5×10-9
Original publication
Genome-wide association study identifies genetic variants which predict the response of bone mineral density to teriparatide therapy. Ann Rheum Dis. Published 20 March 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →